Luis Angel, MD
Pulmonary Disease · New York, NYNPI 1235246307
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Paragonix Technologies, Inc. at 35.6% of the total. Reporting peaked in 2024 at $430 and has fallen 59.1% since, to $176 in 2025. That places this record below the midpoint for pulmonary disease clinicians in NY, where the typical reported total is $756.
Across 21 payments — averaging $53.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paragonix Technologies, Inc.$397
- United Therapeutics Corporation$147
- Boehringer Ingelheim$126
- Boston Scientific$118
- Astellas Pharma US Inc$82
- Merck$54
- plus $191 from 6 others
Across 5 payments — averaging $15,336 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Veloxis Pharmaceuticals, Inc.$64K
- Pneumrx, Inc$12K
What the payments were for
- Food & beverage$1,115100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paragonix Technologies, Inc. | 1 | $397 |
| United Therapeutics Corporation | 1 | $147 |
| Boehringer Ingelheim | 4 | $126 |
| Boston Scientific | 1 | $118 |
| Astellas Pharma US Inc | 3 | $82 |
| Merck | 3 | $54 |
| Advanced Respiratory, Inc | 2 | $46 |
| Genentech USA, Inc. | 2 | $43 |
| Exact Sciences | 1 | $29 |
| Cook Medical LLC | 1 | $29 |
| Vapotherm Inc | 1 | $26 |
| Electromed, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SherpaPak$397
- LIVERguard$397
- LUNGguard$397
- BaroGuard$397
- PancreasPak$397
- ACQUIRE$118
How this compares
$1,115 in reported general payments places this provider in the 50th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Meropenem | 14 | $1,375 |
| Azithromycin | 13 | $108 |
| Carvedilol | 12 | $91 |
| Gabapentin | 13 | $63 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 24 | $58 |
| Hydrochlorothiazide | 16 | $9 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in New York
- Charles PowellNew York$654K
- Bisher AkilNew York$480K
- Sonali SethiNew York$388K
- Johnathan RaskinNew York$338K
- Monica KraftNew York$247K
- Jamie BessichNew York$226K
- Ronald CrystalNew York$213K
- Michael NiedermanNew York$176K
- Wilfredo TalaveraNew York$145K
- Josanna Rodriguez-LopezNew York$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.